Showing results (261-270 of 289) with videos related to

Sort By:
Pageof 29
Journal of Experimental & Clinical Cancer Research : CR|February 6, 2015
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Matteo Santoni, Alessandro Conti, Giuseppe Procopio, et al.
Immunotherapy|February 25, 2020
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa studyMelissa Bersanelli, Sebastiano Buti, Giuseppe Luigi Banna, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 studyCarlo Messina, Martina Catalano, Giandomenico Roviello, et al.
Future Oncology (London, England)|January 19, 2016
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancerAntonello Veccia, Orazio Caffo, Ugo De Giorgi, et al.
Cancer|July 17, 2020
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trialRobert J Motzer, Bernard Escudier, Saby George, et al.
Frontiers in Oncology|March 6, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 studyFrancesco Pantano, Andrea Malgeri, Ugo De Giorgi, et al.
Frontiers in Oncology|February 27, 2024
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: <i>post-hoc</i> analysis of the Meet-URO 15 studyVeronica Murianni, Alessio Signori, Sebastiano Buti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyRobert J Motzer, Camillo Porta, Masatoshi Eto, et al.
Clinical Genitourinary Cancer|November 27, 2024
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 StudyBrigida Anna Maiorano, Martina Catalano, Chiara Mercinelli, et al.
Journal of Translational Medicine|September 30, 2022
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 studySara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
Pageof 29